Literature DB >> 7045659

A platelet-inhibitor-drug trial in coronary-artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency.

J H Chesebro, I P Clements, V Fuster, L R Elveback, H C Smith, W T Bardsley, R L Frye, D R Holmes, R E Vlietstra, J R Pluth, R B Wallace, F J Puga, T A Orszulak, J M Piehler, H V Schaff, G K Danielson.   

Abstract

To prevent occlusion of aortocoronary-artery-bypass grafts, we conducted a prospective, randomized-double-blind trial comparing dipyridamole (instituted two days before operation) plus aspirin (added seven hours after operation) with placebo in 407 patients. Vein-graft angiography was performed in 360 patients (88 per cent) within six months of operation (median, eight days). Within one month of operation, 3 per cent of vein-graft distal anastomoses (10 of 351) were occluded in the treated patients, and 10 per cent (38 of 362) in the placebo group; the proportion of patients with one or more distal anastomoses occluded was 8 per cent (10 of 130) in the treated group and 21 per cent (27 of 130) in th placebo group. This benefit in graft patency persisted in each of over 50 subgroups. Early postoperative bleeding was similar in the two groups. In this trial dipyridamole and aspirin were effective in preventing graft occlusion early after operation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7045659     DOI: 10.1056/NEJM198207083070201

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  60 in total

Review 1.  Gene therapy for vein graft disease.

Authors:  D G Cable; H V Schaff
Journal:  Curr Cardiol Rep       Date:  2001-01       Impact factor: 2.931

Review 2.  Indirect comparison meta-analysis of aspirin therapy after coronary surgery.

Authors:  Eric Lim; Ziad Ali; Ayyaz Ali; Tom Routledge; Lyn Edmonds; Douglas G Altman; Stephen Large
Journal:  BMJ       Date:  2003-12-06

3.  Phosphodiesterase-inhibitors enoximone and piroximone in cardiac surgery: influence on platelet count and function.

Authors:  J Boldt; C Knothe; B Zickmann; C Herold; E Dapper; G Hempelmann
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

4.  Plasma drug and antiplatelet profiles of the original acetylsalicylic acid preparations used in the AMIS, PARIS and German-Austrian trials for secondary prevention of myocardial infarction.

Authors:  R Simrock; K Rehders; H Spahn; E Mutschler; H K Breddin
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-08

6.  Intimal thickening in autogenous vein grafts in rabbits: influence of aspirin and dipyridamole.

Authors:  A J Murday; A H Gershlick; Y D Syndercombe-Court; P G Mills; C T Lewis
Journal:  Thorax       Date:  1984-06       Impact factor: 9.139

Review 7.  Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery.

Authors:  R Davis; R Whittington
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

8.  [Low-dose acetylsalicylic acid (100 mg/day) following aortocoronary bypass operation].

Authors:  M Weber; C von Schacky; R Lorenz; W Meister; J Kotzur; B Reichart; K Theisen; P C Weber
Journal:  Klin Wochenschr       Date:  1984-05-15

Review 9.  Adaptive changes in autogenous vein grafts for arterial reconstruction: clinical implications.

Authors:  Christopher D Owens
Journal:  J Vasc Surg       Date:  2009-10-17       Impact factor: 4.268

Review 10.  Current issues in thrombosis prevention with antiplatelet drugs.

Authors:  G de Gaetano; C Cerletti; E Dejana; J Vermylen
Journal:  Drugs       Date:  1986-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.